Director James Tananbaum Invests $2.52M in Latigo Biotherapeutics at the IPO Price

summarizeSummary

Director and 10% owner James B. Tananbaum bought $2.52 million of Latigo Biotherapeutics stock at the $18.00 IPO price on the first day of trading, a strong vote of confidence from a major insider.

check_boxKey Events · Ownership and Investor Activity · LTGO

• Director Buys $2.52M at IPO Price

  James B. Tananbaum, a director and 10% owner, purchased 140,000 shares at $18.00 for a total of $2.52 million on the IPO date, August 10, 2026.

• Preferred Stock Converts to Common

  Upon the IPO closing, 9,041,328 shares of preferred stock and a convertible note automatically converted into common stock, increasing Tananbaum's indirect holdings to 18,222,656 shares across affiliated funds.

• Insider Aligns with Public Investors

  The open-market purchase at the IPO price demonstrates alignment with new public shareholders and confidence in the company's valuation.

auto_awesomeAnalysis · LTGO · Life Sciences

On the day Latigo Biotherapeutics went public at $18.00 per share, director and 10% owner James B. Tananbaum purchased 140,000 shares for $2.52 million in the open market. This is a real-money commitment at the IPO price, not a derivative conversion or grant. The purchase is significant for a director, signaling conviction in the company's valuation at the offering. Separately, Tananbaum's affiliated funds converted 9.04 million preferred shares and a convertible note into common stock upon the IPO closing, resulting in indirect ownership of 18.2 million shares. The conversion is mechanical and expected, but the open-market buy stands out as a bullish signal from a key insider.